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ABSTRACT: 27 
Objectives 28 
To examine the metastatic and survival rates, eye retention probability and the visual outcome of 29 
juvenile patients after proton beam radiotherapy (PBRT) for uveal melanoma (UM). 30 
Design 31 
Retrospective case-factor matched control study. 32 
Participants and controls 33 
Forty-three patients aged less than 21 years treated with PBRT for UM were compared to 129 34 
matched adult control patients. 35 
Methods 36 
Information on patient demographics and clinical characteristics were recorded before and after 37 
treatment from patients‟ files. The control group was composed of adult patients (>21years) 38 
matched on tumor size (largest tumor diameter +/- 2mm, height +/- 2 mm) and anterior margin 39 
location (iris, ciliary body, pre or post equatorial choroid). For each juvenile patient, three adults 40 
were selected. 41 
Main outcome measures 42 
Comparing outcomes of  juvenile and adult patients in terms of metastatic and eye retention rates 43 
using the log rank statistic, relative survival using the Hakulinen method as well as their visual 44 
outcome. 45 
Results 46 
Forty-three juvenile and 129 control cases were reviewed. The metastatic rate at 10 years was 47 
significantly lower in juvenile UM patients than in adult controls (11% versus 34%; p<0.01) with 48 
an associated relative survival rate of 93 % versus 65% (p=0.02). Six juvenile patients (14%) 49 
developed metastases. One patient underwent enucleation because of a presumed local tumor 50 
recurrence and 4 additional patients because of complications (9.3%). In the adult control group, 51 
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27 % (n=35) of matched patients developed metastases, there were 2 cases of local recurrence 52 
and 16% (n=21) underwent enucleation due to complications. A visual acuity of >0.10 was 53 
maintained in most cases, without any significant differences before or after treatment observed 54 
between both groups. 55 
Conclusions 56 
Following PBRT, metastatic and survival rates are significantly better for juvenile than for adult 57 
patients with UM. Clinically, juvenile and adult eyes react similarly to PBRT, with a comparable 58 
eye retention probability and maintaining a useful level of vision in the majority of cases. This is 59 
the largest case-control study on proton therapy in juvenile eyes to date, and further validates 60 
PBRT as an appropriate conservative treatment for UM in patients less than 21 years of age. 61 
62 
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INTRODUCTION: 63 
Uveal melanoma (UM) is the most common primary ocular malignancy in adults, with an overall 64 
incidence of about 6 new cases per million per year.1,2 In 1962, Apt was the first to report on a 65 
series of 46 UM patients less than 20 years old, which he labeled “juvenile melanoma”.3 The 66 
second cohort, published by Verdaguer in 1965, used 21 years as the upper age limit.4 Ever since, 67 
series of juvenile UM patients have used this same age as the cut-off point; which has the 68 
additional benefit of agreeing with the American Pediatric Academy definition of a child.  69 
Juvenile UM is rare, with only one UM patient in a hundred being less than 21 years old.5-7 As a 70 
consequence, to the best of our knowledge, there are only ten retrospective series reporting on 71 
juvenile UM patients.3-12 In most of these reports, young patients were treated with enucleation, 72 
brachytherapy or surgical resection. Following our publication in 1992,8 only one other study has 73 
described the clinical profile and prognosis of juvenile UM eyes (n=17) treated with proton beam 74 
radiotherapy (PBRT).9 75 
While all reports concluded that young patients tended to have a lower metastatic rate, very little 76 
information is available on eye retention probability or visual acuity.8,9 The first aim of this study 77 
is to compare the long term metastatic and survival rates for a group of juvenile and matched 78 
control adult patients following PBRT for UM. The second aim is to examine whether 79 
ophthalmologic outcomes such as the eye retention probability, complications requiring surgery 80 
or visual function of these juvenile patients differ from their adult counterparts.  81 
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METHODS: 82 
Patients 83 
In this single center, retrospective, case-control study, files were reviewed from all patients 20 84 
years old or less at the time of their UM diagnosis who were treated with PBRT since 1984. For 85 
each juvenile patient, three matched adult control patients were selected. Matching was based on 86 
tumor size (largest tumor diameter +/- 2 mm; height +/- 2 mm) and location of the anterior 87 
tumor margin (iris, ciliary body, pre or post equatorial choroid). Eyes with prior tumor resection 88 
or brachytherapy were excluded. Ethical approval for this study was obtained from the 89 
„Commission Cantonale d'Éthique‟, Canton of Vaud, Switzerland. 90 
Treatment and Follow-up 91 
Clinical baseline visits, tantalum clip surgery and follow-up took place at the Ocular Oncology 92 
Unit of the Jules-Gonin Eye Hospital (University of Lausanne, Switzerland).  PBRT was 93 
performed at the Paul Scherrer Institute (Villigen, Switzerland), with a 60 Gy (RBE) delivered in 94 
four fractions, on four consecutive days.13,14 95 
Standard baseline and follow-up visits consisted of a complete clinical ophthalmologic 96 
examination, color tumor photography and ultrasonography. Examinations were performed 97 
before the tantalum clip surgery, six months after PBRT, and then annually for 15 years in our 98 
hospital. Juvenile patients lost to follow-up (or their family) were contacted by telephone with 99 
regard to information such as metastatic occurrence, vital status and eye retention. To obtain 100 
ophthalmic details, a letter was sent to their local ophthalmologist. Metastatic screening, 101 
consisting of liver function tests (aspartate transaminase, alanine transaminase, alkaline 102 
phosphatase, gamma glutamyltransferase and lactate dehydrogenase) and imaging 103 
(ultrasonography or computed tomography scan), was done before treatment, twice a year during 104 
the first five years and then once a year for another ten years after PBRT. Any clinical diagnosis 105 
of metastases was confirmed by biopsy. 106 
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Baseline and outcome measures included age, gender, best corrected visual acuity (BCVA) with 107 
the Snellen chart, intraocular pressure (IOP), tumor size, tumor location, tumor related 108 
complications prior to treatment (intraocular inflammation, glaucoma, cataract, intravitreal 109 
hemorrhage, retinal detachment, rupture of Bruch‟s membrane), radiation related complications, 110 
eye retention, metastatic occurrence and vital status. 111 
Statistical analysis 112 
Metastatic disease, relative survival and eye retention probability were examined. Additionally we 113 
looked at local tumor control as well as tumor and treatment related complications and visual 114 
acuity. Patients lost to follow-up were censored at their last visit. If a patient had died, these data 115 
were censored at the time of his last visit. Metastatic rates and eye retention rates were estimated 116 
using the Kaplan-Meier method and compared between juvenile and adult control groups using 117 
the log rank test statistic at a 5% level of significance using the “survival” R package (R 118 
Foundation for Statistical Computing, Vienna, Austria).15 To correct for increased age-related 119 
mortality rates when comparing both groups, we looked at relative rather than observed survival 120 
rates (relative survival = observed survival/expected survival, with expected survival being the 121 
survival of a general population group with age and gender characteristics similar to the studied 122 
cohort). Relative survival statistics (Hakulinen method) were calculated using the “relsurv” R 123 
package,16 where the rate table was calculated using Swiss demographics from the Human Mortality 124 
Database.17 Univariate and multivariate analyses were performed using the glm base package; 125 
significance was assessed using the chi-squared test statistics.  126 
Search of Literature 127 
A computerized search was performed in MEDLINE using the keywords “Juvenile”, 128 
“Adolescent”, “Children”, “Uveal melanoma”, and “Proton beam radiotherapy”. The 129 
bibliography of each article was also reviewed. Articles published prior to 1966 were identified 130 
using the Excerpta Medica Abstract Journal, Ophthalmology (Section 12 EMBASE), with the 131 
same first three keywords.  132 
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RESULTS: 133 
Between 1984 and 2011, 44 of the 5340 UM patients treated with proton therapy were 20 years 134 
or younger at the time of diagnosis (0.8%). The first 11 of those patients have already been 135 
reported upon in a previous paper, one of whom, previously treated with brachytherapy, was 136 
excluded from this study.8 There were no differences in gender or laterality between the juvenile 137 
and adult control UM groups (p0.37; chi squared test, Table 1, available at 138 
http://aaojournal.org). In both groups the majority of tumors were exclusively located in the 139 
choroid whereas approximately 20% reached the iris (Table 2, available at 140 
http://aaojournal.org). Significantly more adult than juvenile eyes presented a rupture of Bruch‟s 141 
membrane. Mean follow-up time for the juvenile UM group was 155 months (range: 6- 336), and 142 
for the adult control group 79 months (range: 4- 281). 143 
Six of 43 juvenile patients developed liver metastases (14%) between 2 and 14 years after 144 
radiotherapy, five of whom had died less than a year later (12%) (Table 3). The surviving patient 145 
was treated with immunotherapy, Fotemustine® chemotherapy and radiofrequency, and is in 146 
remission, eight years after the biopsy proven presence of ganglion and liver metastases. The 147 
primary uveal tumors of these patients were classified19 as T3 (N=2) or T4 (N=4) and half of 148 
them involved the ciliary body. A baseline retinal detachment of at least 2 quadrants was present 149 
in four of these patients, which persisted until the last visit for three of them. No juvenile 150 
patients with a T1 or T2 tumor developed metastases. On the other hand, in the adult control 151 
group, 35 patients developed metastases (27%), all of whom died less than 3 years later. Ten of 152 
these 35 adults had a T2 tumor, the remainder presenting a T3 (N=6) or a T4 (N=19) tumor. 153 
Kaplan-Meier curves comparing the metastatic rates in both groups (Figure 1) show a statistically 154 
significant difference, with a metastatic rate in juvenile patients of 8% at 5 years (95% Confidence 155 
Interval (CI) [0-16], n=34), 11% at 10 years (95% CI [0-20], n=25) and 19% at 15 years (95% CI 156 
[3-32], n=18), whereas the adult controls had a metastatic rate of 24% at 5 years (95% CI [16-33], 157 
n=67), 34% at 10 years (95% CI [23-43], n=29), and 48% at 15 years (95% CI [28-63], n=5). 158 
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Splitting the juvenile group into children (<16years) and young adults (16-20 years), a subgroup 159 
analysis was performed (Table 4). No metastases occurred in the children‟s group, whereas from 160 
16 years onwards the juvenile patients joined the adult controls with regard to the risk of 161 
developing metastases. 162 
Looking for metastatic risk factors using univariate analysis, age was confirmed to be a significant 163 
risk factor for metastases in the juvenile group (p=0.04) and not in the adult control group 164 
(p=0.41). Also the persistence of a large (≥2 quadrants) retinal detachment 6 months after PBRT, 165 
was a metastatic risk factor for the former (p=0.01) and not for the latter (p=0.66), and remained 166 
significant on multivariate analysis, when age had been taken into account for the juvenile group 167 
(p=0.03). However, while tumor size was not a significant risk factor in patients less than 21 168 
years old (p=0.99), it did prove to be a significant risk factor in the adult control group 169 
(p<0.001). 170 
Juvenile UM patients also had a significantly better survival than their adult controls (Figure 2). 171 
The relative survival rate in the juvenile UM group was 93 % at 5 years (95% CI [84-100], n=35), 172 
93% at 10 years (95% CI [85-100], n=27) and 85% at 15 years (95% CI [72-99], n=20). In the 173 
adult control group, relative survival rate was 77% at 5 years (95% CI [69-86], n=74), 65% at 10 174 
years (95% CI [57-79], n=27) and 50% at 15 years (95% CI [35-71], n=6). 175 
Local tumor control was achieved in all but one juvenile patient, who had his eye removed 16 176 
months after PBRT by his own ophthalmologist because of a presumed local recurrence. During 177 
15 years of follow-up, this patient has not developed metastases. In the adult group, two patients 178 
presented with a local recurrence, in addition to concurrent liver metastases of which they died 179 
less than one year later. 180 
Five juvenile patients (12%) were enucleated between 1 to 19 years following PBRT. One of 181 
them due to a presumed local recurrence, and four others because of complications such as 182 
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neovascular glaucoma (n=2), phthisis bulbi (n=1) and a painful pseudophakic bullous 183 
keratopathy in an otherwise non-functional eye (n=1). In the adult control group, 21 eyes (16%) 184 
were enucleated, due to neovascular glaucoma (n=15), phthisis bulbi (n=5) and painful end stage 185 
glaucoma (n=1).  186 
While the eye retention rate was higher in the juvenile UM group, a comparison of the Kaplan-187 
Meier eye retention curves did not demonstrate a statistically significant difference (p=0.08) 188 
(Figure 3). An eye retention rate of 90% at 5, 10 and 15 years (95% CI [80-100]; n=31, 24, 18 189 
respectively) was observed in the juvenile group, where all but one enucleation took place within 190 
the first 5 years following proton therapy. In the adult group the eye retention rate was 86% 191 
(95% CI [80-93]), 77% (95% CI [68-88]) and 67% (95% CI [50-90]) at 5, 10 and 15 years 192 
respectively. 193 
Table 5 gives an overview of most of the tumor and radiation related complications in both 194 
groups, as well as the surgical interventions required due to these complications. Minor aesthetic 195 
side effects such as radiation related madarosis or eyelid atrophy are not listed. Tables 6 and 7 196 
(table 7 is available at http://aaojournal.org) summarize some basic ocular parameters, such as 197 
BCVA, IOP, lens status, presence of retinal detachment and/or vitreous/subretinal hemorrhage 198 
within both the juvenile and adult control UM group at three time points throughout follow-up, 199 
i.e. at baseline and at the first and last control visit after PBRT. With the exception of the 200 
prevalence of more lens opacities in the adult control, no significant differences were identified 201 
between either group. 202 
DISCUSSION: 203 
The comparison of the metastatic and relative survival rates between juvenile and adult control 204 
UM patients demonstrated a significantly better prognosis for patients less than 21 years old. In 205 
particular, a 10-year relative survival rate of 93% was observed in the juvenile patients, opposed 206 
to 65% in the matched adult controls. Similarly the 10-year metastatic rate was much lower in the 207 
juvenile group. This supports the 5-year metastatic rates already reported by Kaliki,11 as well 208 
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those by Vavvas reported at a median of 16 years.9 Shields et al. have previously highlighted the 209 
difficulties of comparing survival rates reported in the non-matched series,3-8, 12 as it can be 210 
susceptible to bias,11 and lead to specious results.10 For example, juvenile UM series do contain a 211 
greater proportion of iris melanoma which would contribute to a better vital prognosis,5,7 By 212 
matching for tumor characteristics, as done in this article, this source of bias has been reduced. 213 
Table 8 (available at http://aaojournal.org) provides a summary of the mortality rates reported 214 
in the ten available juvenile UM series. Important to note is that metastases continue to occur 215 
after 10 years‟ follow-up (Figure 1) in both groups. This finding stresses the importance of 216 
checking the mean follow-up before interpreting the metastatic rates of studies on patients 217 
treated for uveal melanoma. 218 
Examining risk factors for metastases within the juvenile UM group, showed that increasing age 219 
proved to be a significant risk factor, which has previously been reported by Kaliki et al.11 In 220 
contrast to the traditional 21st birthday of political majority, Swiss pediatricians stop following 221 
their patients after their 16th birthday, considering that most of them by then have reached 222 
biological maturity. Respecting this distinction, the juvenile group was split into children 223 
(<16years) and young adults (16-21years), and the difference in vital prognosis of -mostly 224 
prepubescent- children compared to the adults became even more evident; here no UM children 225 
developed metastases. On reviewing the literature, including all case reports, it was found that 226 
approximately 470 cases of juvenile UM have been reported worldwide.19-57 Of these, only 14 227 
children (<16 years; 3%) were reported to have died from metastatic disease, 3,5,19-23,55 (Table 9, 228 
available at http://aaojournal.org) though it should be noted that not all juvenile series specify 229 
the age at UM diagnosis of their patients having died from metastases. 230 
These results have led some authors to speculate that children are somehow „protected‟ from 231 
metastatic disease and may have a more „robust‟ immune system keeping micro-metastases under 232 
better control.9,11 Dimaras et al recently published the cytogenetic results after enucleation of an 233 
epithelioid juvenile melanoma, reporting an absence of monosomy 3 or trisomy 8, indicating a 234 
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lack of the somatic mutations usually found in adults. This may be related to the favorable 235 
prognosis of children.25 236 
Retinal detachments which persisted six months after PBRT, were shown to be a significant risk 237 
factor for developing metastases in the juvenile group. Though retinal detachment has been 238 
shown to be a function of tumor size,58 the correlation between its persistence after radiotherapy 239 
and shrinking tumor size or metastatic risk has not been previously studied. In this report, tumor 240 
size was not correlated with a higher metastatic risk in juvenile eyes, in contrast to the adult 241 
matched control group. This lack of correspondence between tumor size and metastases in 242 
juvenile UM eyes was previously reported by Kaliki et al.11 Despite this outcome it should be 243 
noted that no patient less than 21 years old with a small T1 or T2 tumor has ever been reported 244 
to develop metastases. 245 
This case-matched control study is the first to compare eye retention rates after conservative 246 
radiotherapy between juvenile and adult control patients with UM. Though in the former group 247 
88% of patients kept their eye against only 76% in the latter, this difference was not statistically 248 
significant. No significant differences in visual outcome or other ocular parameters were found 249 
between juvenile and adult eyes, indicating that following PBRT, juvenile UM eyes do not require 250 
a different follow-up and/or management than adult eyes. 251 
Since this study is not a randomized clinical trial, there are likely sources of bias and variability, 252 
originating from the use of historical data or possible differences in adherence or attendance 253 
which could affect the study outcomes. Considering the rarity of juvenile uveal melanoma a 254 
randomized clinical trial is not achievable and the size of this cohort is substantial. In the 255 
statistical analysis, every effort has been made to control for the known risk factors of metastases, 256 
and decreased survival. 257 
To the best of our knowledge, this is the largest cohort of juvenile UM patients treated with 258 
PBRT.8, 9 Here it was shown that juvenile patients treated with PBRT have a significantly better 259 
prognosis in terms of survival and metastatic rates than a corresponding adult group, especially 260 
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prepubescent children. PBRT also maintains useful vision in the majority of cases, with an 261 
excellent local tumor control and similar eye retention rates as reported in the adult population. 262 
This long term case-control study confirms that PBRT is an appropriate conservative treatment 263 
for UM patients less than 21 years old. 264 
 265 
266 
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Table 1: Patient characteristics and baseline symptoms 
Patient characteristics Juvenile UM group (N=43)      Adult control UM group (N=129) 
Mean age at diagnosis (±SD) [range] 17.3 years (±3.5 ) [9-21] 50.4 years (±10.2) [29-81] 
Gender: Male/Female ratio 20/23 (47/53%) 64/65 (50/50%) 
Previous primary cancer 1 (Burkitt lymphoma)  1 (Hodgkin’s lymphoma) 
Dysplastic nevus syndrome 1 (2%)  0  
Ocular melanocytosis 2 (5%)  5 (4%) 
Affected Eye (Right/Left) 15/28 (35/65%) 55/74 (43/57%) 
Baseline Symptoms 
 Loss of vision 
 Metamorphopsia 
 Flashes of light 
 Pain 
 Floaters 
 None  
 
 29 (67%) 
 6 (14%) 
 4 (9%) 
 0  
 1 (2%) 
 13 (30%) 
 
 94 (73%) 
 28 (22%) 
 44 (34%) 
 1 (1%) 
 17 (13%) 
 11 (8%) 
SD = Standard Deviation, UM = Uveal Melanoma. 
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Table 2: Baseline tumor characteristics comparing the juvenile and adult control uveal melanoma groups 
Baseline 
tumor characteristics 
Juvenile UM group (N=43) Adult control UM group (N=129) p-value 
LTD (±SD) [range] 17.0 mm (±4.3) [8-24] 16.7 mm (±4.2) [8-23] p=0.80* 
Height (±SD) [range] 6.9 mm (±3.9) [2-20] 6.8 mm (±2.8) [2-14] p=0.93* 
Location of anterior tumor 
margin 
 Iris 
 Ciliary body 
 Anterior choroid 
 Posterior choroid 
 
 
 9 (21%) 
 7 (16%) 
 9 (21%) 
 18 (42%) 
 
 
 23 (18%) 
 24 (18%) 
 28 (22%) 
 54 (42%) 
  
  
  
 
 
p=0.97† 
Distance to the optic disc 
 Infiltration 
 In contact 
 >0 mm & <3.6 mm 
 ≥3.6mm 
 
 0  
 7 (16%) 
 9 (21%) 
 27 (63%) 
 
 12 (9%) 
 23 (18%) 
 27 (21%) 
 67 (52%) 
  
  
  
 
p=0.19† 
Distance to the macula 
 In contact 
 >0mm & <3.6mm 
 ≥3.6mm 
 
 10 (23%) 
 10 (23%) 
 23 (54%) 
 
 43 (33%) 
 35 (27%) 
 51 (40%) 
  
  
  
 p=0.26† 
Rupture of Bruch’s membrane  5 (12%)  44 (34%) p=0.02 
Extrascleral extension 0 8 (6%) p=0.19 
TNM stage‡ 
 1 
 2 
 3 
 4 
 
 4 (9%) 
 13 (30%) 
 9 (21%) 
 17 (40%) 
 
 4 (3%) 
 44 (34%) 
 31 (24%) 
 50 (39%) 
 
 
 
 
 
p=0.99† 
* = two-sample t-test, † = Chi-squared test ‡ = TNM staging of uveal melanoma according to the 7th ed. of 
the American Joint Committee on Cancer cancer staging 2010.19 TNM = Tumor size, Nodes, Metastasis, 
SD = Standard Deviation, UM = Uveal Melanoma, LTD = Largest Tumor Diameter. 
 
Table 2-online only pdf
Click here to download Table: table 2 corrected - Copie.pdf
Table 3: Details of the juvenile uveal melanoma patients having developed metastases 
Gender Age at 
diagnosis 
(years) 
UM location Tumor size (mm): 
LTD x Height 
Metastatic free 
survival after 
PBRT (years) 
Metastatic 
survival 
(years) 
Vital 
status 
F 20 Ciliary body and 
anterior choroid 
21.0 x 8.5 12 <1 Dead 
F 20 Ciliary body and 
anterior choroid 
16.8 x 8.5 2 <1 Dead 
F 20 Anterior and 
posterior choroid 
15.6 x 6.8 7 8 Alive 
M 20 Anterior and 
posterior choroid 
19.0 x 4.6 5  <1 Dead 
M 18 Posterior choroid 19.0 x 9.0 14 <1 Dead 
M 20 Ciliary body and 
anterior choroid 
23.0 x 10.0 2 <1 Dead 
UM = Uveal Melanoma, LTD = Largest Tumor Diameter, PBRT = Proton Beam RadioTherapy, F = 
Female, M= Male 
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Table 4: Subgroup analysis for metastatic occurrence in function of age. 
 
 
 
Subgroup by age (years) Number of patients 
in this group 
Number of patients with 
metastases (%) 
90% 
Confidence 
Intervals [%] 
0-15 14 0 [0-16] 
16-20 29 6 (21%) [11-35] 
21+ 129 36 (28%) [22-35] 
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Table 5: Tumor and radiation related complications following proton beam radiotherapy in juvenile and 
adult control uveal melanoma patients 
 Tumor and radiation related complications Juvenile UM group (N=43) Adult control UM group (N=129) 
Local UM recurrence 1 (2%) 2 (2%) 
Retinal ischemia requiring laser treatment 16 (37%) 20 (16%) 
Neovascular glaucoma 8 (19%) 24 (19%) 
Phthisis bulbi 2 (5%) 5 (4%) 
Scleral melt 1 (2%) 3 (2%) 
Chronic inflammation 1 (2%) 0 
Pseudophakic bullous keratopathy  1 (2%) 0 
Complication treatments   
Enucleation for local melanoma recurrence 1 (2%) 0 
Enucleation for other complications  4 (9%) 21 (16%) 
Other interventions 
 Strabismus surgery 
 Glaucoma surgery 
 Retinectomy/tumorectomy 
 Scleral graft 
 Phacoemulsification 
 Laser for conjunctival telangiectasia 
 Vitrectomy for massive vitreal hemorrhage 
9 (21%) 
 1 
 2    
 1  
 1  
 8 
 2 
 1  
 
17 (13%) 
 
 0  
 1    
 1  
 0  
 12 
 NA  
 3   
UM = Uveal Melanoma, NA = data Not Available. 
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Table 6: Ocular status of the juvenile uveal melanoma patients at baseline and at the first and 
last control visit after proton beam radiotherapy  
 
(PBRT).and last control visit after proton beam 
radiotherapy (PBRT) 
Ocular parameter Baseline 6 months after PBRT Last control  visit (excluding 5 
enucleated eyes) 
Mean BCVA 
 NLP 
 ≤0.10 
 >0.10 
0.5 (±0.4) [0-1.25] 
 0 
 5 (12%) 
 38 (88%) 
0.4 (±0.4) [0-1.5] 
 2 (5%) 
 11 (25%) 
 30 (70%) 
0.2 (±0.4) [0-1] 
 7 (18%) 
 15 (40%) 
 16 (42%) 
Mean IOP in mmHg 14.4 (±6.4) [7-43] 14.1 (±4.7) [2-25] 14.0(±6.8) [2-43] 
Lens opacities 
 Absent 
 Present 
 Pseudophakic 
  
 42 (98%) 
 1 (2 %) 
 0 
 
 33 (77%) 
 10 (23%) 
 0 
 
 17 (45%) 
 15 (39%) 
 6 (16%) 
Retinal detachment 
 None 
 1 quadrant 
 ≥2 quadrants 
 
 18 (42%) 
 12 (28%) 
 13 (30%) 
 
 27 (63%) 
 7 (16%) 
 9 (21%) 
 
 30 (79%) 
 2 (5%) 
 6 (16%) 
Vitreous or subretinal  
hemorrhage (Yes/No) 
1/42 3/40 1/37 
PBRT= Proton Beam RadioTherapy, BCVA = Best Corrected Visual Acuity, NLP = No Light 
Perception, IO  = IntraOcular Pressure 
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Table 7: Ocular status of the adult control uveal melanoma patients at baseline and at the first and last 
control visit after proton beam radiotherapy (PBRT). 
Ocular parameter Baseline 6 months after PBRT Last control  visit 
(excluding 21 enucleated 
eyes) 
Mean BCVA 
 NLP 
 ≤0.10 
 >0.10 
0.6 (±0.4) [0-1.5] 
 0  
 25 (19%) 
 104 (81%) 
0.4 (±0.4) [0-1.5] 
 6 (5%) 
 52 (40%) 
 71 (55%) 
0.3 (±0.4) [0-1.25] 
 19 (21%) 
 22 (24%) 
 51 (55%) 
Mean IOP in mmHg 14.0 (±3.4 ) [7-28] 15.7 (±8.0 ) [4-66] 16.3 (±8.1) [0-46] 
Lens opacities 
 Absent 
 Present 
 Pseudophakic 
 
 112 (87%) 
 16 (12%) 
 1 (1%) 
 
 86 (67%) 
 42 (32%) 
 1 (1%) 
 
 33 (36%) 
 48 (52%) 
 11 (12%) 
Retinal detachment 
 None 
 1 quadrant 
 2 quadrants 
 
 60 (47%) 
 32 (25%) 
 37 (28%) 
 
 74 (57%) 
 16 (12%) 
 39 (31%) 
 
 79 (86%) 
 2 (2%) 
 11 (12%) 
Vitreous or subretinal 
hemorrhage (Yes/No) 
17/112 7/122 7/85 
BCVA = Best Corrected Visual Acuity, NLP = No Light Perception, IOP = IntraOcular Pressure 
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Summary of the 10 available series reporting on juvenile uveal melanoma: 
Reference Number 
of patients 
UM Location Treatment Mortality 
(%) 
Mean 
Follow-up 
(years) 
*Petrovic 2013 43 9 iris 
7 CB 
9 Anterior Choroid 
18 Posterior Choroid 
Proton beam radiotherapy 7 13 
*Kaliki  
2012 11 
122 30 Iris 
10 CB 
13 Anterior Choroid 
69 Posterior choroid  
NA 8 5.25 
*Vavvas  
2010 9 
17 1 CB 
16 Choroid 
Proton beam radiotherapy 0 16 
†Pogrzebielski 
2006 7 
11 6 Iris 
2 Iris and CB 
3 Choroid 
Surgical resection 
Surgical resection 
Enucleation/Brachytherapy 
0 5 
†Singh  
2000 10 
63 16 Iris 
13 CB 
34 Choroid 
39 Enucleation 
9 Brachytherapy 
3 Surgical resection 
6.4 4.5 
Gailloud  
1992 8 
11 3 CB 
8 Choroid 
Proton beam radiotherapy NA 1.9 
Shields  
1991 6 
40 5 Iris 
35 Choroid 
24 Enucleation 
7 Surgical resection 
3 Brachytherapy 
6 No treatment 
2.5 5.7 
Barr  
1981 5 
78 36 Iris 
42 CB/Choroid 
 
Enucleation and Surgical 
resection 
22 16 
Leonard  
1975 12 
7 2 Iris 
5Choroid 
2 Iridectomy 
5 Enucleation 
0 3 
Verdaguer 
 1965 4 
7 2 Iris 
2 CB 
3 Choroid 
2 Iridectomy 
5 Enucleation 
0 3 
Apt  
1962 3 
46 19 Iris 
27 CB/Choroid 
NA 15 NA 
* matched control group; †historical control group; data not available (NA), UM = Uveal Melanoma, CB = Cilary 
Body. 
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Table 9: Review of the literature: children less than 16 years old who died from metastatic disease 
 
Reference Sex/Age  
(years) 
Tumor size Tumor 
location 
Treatment 
 
Metastatic 
occurrence 
(years) 
Apt, 1962 3 F/2 
M/11 
NA 
NA 
Iris 
Choroid 
Enucleation 
Enucleation 
6 
NA 
Barr, 1981 5 NA/3 
NA/<16 
NA/<16 
NA/5 
NA/2 
NA 
NA 
NA 
NA 
NA 
Choroid 
Choroid 
Choroid 
Iris 
Iris 
Enucleation 
Enucleation 
Enucleation 
NA 
NA 
NA 
Colombo, 1935 20 F/3 NA Choroid Enucleation 0.5 
Cury, 1959 21 M/5 
M/11 
16x17 mm 
12x16 mm 
CB 
Choroid 
Enucleation 
Enucleation 
NA 
Fenske, 1964 56 F/11 NA Iris Enucleation 6 
Rosembaum, 1988 22 M/5 NA Iris, CB Enucleation 0.8 
Broadway, 1991 23 M/Congenital 40x50 mm Choroid Enucleation Present at birth 
Grabowska, 2011 24 M/1 15 mm (H) Iris Enucleation 0.5 
NA = data Not Available, F = Female, M = Male, CB = Ciliary Body, H = Height 
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FIGURE LEGENDS 
 
Figure 1: Kaplan-Meier metastatic rate curves comparing the juvenile and adult control uveal 
melanoma groups. 
Figure 2: Relative survival rates comparing the juvenile and adult control uveal melanoma groups 
(Hakulinen method). 
Figure 3: Kaplan-Meier eye retention curves comparing the juvenile and adult control uveal melanoma 
groups. 
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